HOME >> MEDICINE >> NEWS
Many drugs prescribed for chronic insomnia are not approved for that purpose

WINSTON-SALEM, N.C. The most frequently used drugs for treating chronic insomnia have never been approved for that purpose by the U.S. Food and Drug Administration (FDA), according to a sleep expert from Wake Forest University Baptist Medical Center.

Vaughn McCall, M.D., M.S., professor and chairman of the Department of Psychiatry and Behavioral Medicine, told a special consensus panel at the National Institutes of Health (NIH) that he could find no evidence that randomized controlled clinical trials had ever been conducted for five of the 10 pharmaceuticals prescribed most often for chronic insomnia.

None of the 10 are currently approved for insomnia, though all are FDA-approved as antidepressants, antipsychotics or sedatives, he said.

The NIH State-of-the-Science Conference on Manifestations and Management of Chronic Insomnia in Adults, sponsored by the National Institute of Mental Health and Office of Medical Applications Research, will continue through Wednesday, seeking to build consensus on a series of questions on chronic insomnia.

"There is widespread use of off-label prescribed medications for insomnia," said McCall, who directs the sleep laboratory at Wake Forest Baptist. But he said that evidence to support their effectiveness is poor.

He said that during the 1990s, the use of FDA-approved sleep medications called hypnotics declined by 54 percent between 1987 and 1996, "while the use of trazodone (Desyrel) and other sedating antidepressants rose by 146 percent. This trend continued through 2002, such that trazodone became the most frequently used medication for the treatment of insomnia."

He said that 78 percent of psychiatrists now make trazodone their first choice.

"In addition to trazodone, a wide variety of antidepressants, antipsychotics and sedatives gained favor for the treatment of insomnia despite the fact that none of these medications are approved for the treatment of insomnia."

McCall said the widespr
'"/>

Contact: Robert Conn
rconn@wfubmc.edu
336-716-4587
Wake Forest University Baptist Medical Center
14-Jun-2005


Page: 1 2

Related medicine news :

1. UIC researchers to develop new drugs to fight bioterrorism
2. Statin drugs may delay progressive artery damage in children
3. Study finds HIV protease inhibitor drugs may adversely affect the scaffolding of the cell nucleus
4. Experts call for urgent research into anti-epileptic drugs given to children
5. UCLA researchers develop new nanomaterials to deliver anti-cancer drugs to cells
6. Antipsychotic drugs increase risk of death in older people with dementia
7. Antipsychotic drugs increase risk of death in older people with dementia
8. Gene variations point to why lung cancer drugs work better in Japanese vs. US patients
9. Panel offers guidelines on skin reactions to new class of cancer drugs
10. Blood-thinning drugs need closer monitoring
11. Comparison of patients access to new and better cancer drugs reveals inequalities between countries

Post Your Comments:
(Date:10/31/2014)... (HealthDay News) -- A comparison of two of the ... laparoscopic gastric bypass helped patients shed more excess pounds ... of short-term complications and long-term hospitalizations. Gastric-bypass surgery ... so your body does not absorb all the calories ... of Health. Gastric banding is a type of weight-loss ...
(Date:10/31/2014)... By Steven Reinberg HealthDay ... skin condition eczema may increase slightly the risk of broken bones ... of 34,500 adults, researchers found that among 7 percent of people ... had a bone or joint injury and 0.6 percent had an ... people without eczema, those with the skin condition had more than ...
(Date:10/30/2014)... for injuries and damage to the joints, including articular ... a hard material that caps the ends of bones ... engineers, exploring ways to toughen up engineered cartilage and ... developments this week in the journal Proceedings of ... with engineered tissue is that the mechanical properties are ...
(Date:10/30/2014)... by NIH grantees predicts that women must take the ... vaginal sex, whereas just two doses per week can ... finding helps explain why two large clinical trials testing ... show efficacy. Participants in the VOICE and ... antiretroviral) for HIV prevention were counseled to take one ...
(Date:10/30/2014)... Don Allred Insurance, a leading provider ... for North Carolina residents, is excited to announce the ... Hill Mall. The new branch has been up and ... through all facets of the insurance selection process from ... Scott Allred couldn’t be happier with the timing of ...
Breaking Medicine News(10 mins):Health News:Study Compares 2 Common Weight-Loss Surgeries 2Health News:Study Compares 2 Common Weight-Loss Surgeries 3Health News:Eczema Tied to Bone Fracture Risk in Study 2Health News:Making lab-grown tissues stronger 2Health News:Model by NIH grantees explains why HIV prevention dosing differs by sex 2Health News:Allred Insurance Satellite Office Grand Opening 2
(Date:10/31/2014)... -- Encision Inc. (OTCQB:ECIA), a medical device company owning patented ... minimally invasive surgery, today announced financial results for its ... The Company posted quarterly net revenue of $2.279 ... or $(0.04) per share. These results compare to net ... $50 thousand, or $(0.01) per share, in the year-ago ...
(Date:10/31/2014)... October 30, 2014 ... the addition of the  "Process Validation in the ... offering.      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key ... Risk Based Approach to Process Validation for Pharmaceutical ... FDA Process Validation Guidance ...
(Date:10/31/2014)... 2014  AbbVie (NYSE: ABBV ) ... ended Sept. 30, 2014. "Our ... business with double-digit growth from HUMIRA and several ... 14 percent in the quarter excluding lipids," said ... AbbVie.  "We exceeded our outlook for the quarter ...
Breaking Medicine Technology:Encision Reports Second Quarter Fiscal Year 2015 Results 2Encision Reports Second Quarter Fiscal Year 2015 Results 3Encision Reports Second Quarter Fiscal Year 2015 Results 4Encision Reports Second Quarter Fiscal Year 2015 Results 5Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
Cached News: